

PRODUCT INFORMATION




GFAP Monoclonal Antibody (Clone 8E6)

Item No. 28847


Overview and Properties

Contents:	This vial contains 100 µg of protein G-purified monoclonal antibody.
Synonyms:	ALXDRD, Glial Fibrillary Acidic Protein, Intermediate Filament Protein
Immunogen:	Full length recombinant human GFAP protein
Species Reactivity:	(+) Human, mouse; other species not tested
Uniprot No.:	P14136
Form:	Liquid
Storage:	-20°C (as supplied)
Stability:	≥3 years
Storage Buffer:	PBS, pH 7.2, with 50% glycerol and 0.02% sodium azide
Clone:	8E6
Host:	Mouse
Isotype:	IgG2a
Applications:	ELISA, Immunohistochemistry (IHC), and Western blot (WB); the recommended starting dilution for ELISA and WB is 1:1,000 and 1:200 for IHC. Other applications were not tested, therefore optimal working concentration/dilution should be determined empirically.

Images



Lane 1: GFAP Recombinant Protein (10 ng)
Lane 2: GFAP Recombinant Protein (25 ng)
Lane 3: GFAP Recombinant Protein (50 ng)
Lane 4: Human Brain Lysate (5 µg)



Immunohistochemistry analysis of formalin-fixed, paraffin-embedded (FFPE) human brain, cortex, tissue after heat induced antigen retrieval in pH 6.0 citrate buffer. After incubation with GFAP Monoclonal Antibody (Clone 8E6) (Item No. 28847) at a 1:200 dilution, slides were incubated with biotinylated secondary antibody, followed by alkaline phosphatase-streptavidin and chromogen (DAB).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/06/2023

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Glial fibrillary acidic protein (GFAP) is a protein encoded by the *GFAP* gene in humans and a member of the class III intermediate filament (IF) protein family.¹ It is composed of an N-terminal head domain, a highly conserved α -helical rod domain, and a C-terminal tail domain that mediate GFAP self-assembly, dimerization, and oligomerization, respectively.^{2,3} GFAP is expressed in, and has commonly been used as a pan marker for, mature astrocytes.¹ GFAP IFs form a dynamic network of cytosolic filament proteins that collectively provide structure and strength to the cytoskeleton of astrocytes, thus supporting their morphology and function.¹ Isolated astrocytes from neonatal *Gfap*^{-/-} mouse brain have reduced numbers of IFs and IF bundles, increased proliferation, and loss of contact-inhibited growth.^{4,5} *Gfap*^{-/-} mice develop more diffuse and infiltrative brain lesions compared to wild-type littermates in a mouse model of experimental autoimmune encephalomyelitis (EAE).⁶ Mutations in the rod and tail domains of *GFAP* have been associated with Rosenthal fiber formation, a hallmark of Alexander disease.⁷ Transgenic overexpression of *Gfap* in mice increases the expression of certain cytokines and antioxidative enzymes in the olfactory bulb and has been used as a mouse model of Alexander disease.⁸ GFAP can be citrullinated on the arginine residue at position 270 (R270) and at R416 by protein arginine deiminase 1 (PAD1; Item No. 10784) and PAD2 (Item No. 10785).⁹ Citrullinated GFAP has been found in rat cerebral cortex in a model of traumatic brain injury, as well as in postmortem hippocampus from patients with Alzheimer's disease.^{9,10} Cayman's GFAP Monoclonal Antibody (Clone 8E6) can be used for ELISA, Immunohistochemistry (IHC), and Western blot (WB) applications. The antibody recognizes GFAP at ~50 kDa from human and murine samples.

References

1. Hol, E.M. and Capetanaki, Y. Type III intermediate filaments desmin, glial fibrillary acidic protein (GFAP), vimentin, and peripherin. *Cold Spring Harb. Perspect. Biol.* **9(12)**, a021642 (2017).
2. Inagaki, M., Nakamura, Y., Takeda, M., et al. Glial fibrillary acidic protein: Dynamic property and regulation by phosphorylation. *Brain Pathol.* **4(3)**, 239-243 (1994).
3. Chen, W.-J. and Liem, R.K.H. The endless story of the glial fibrillary acidic protein. *J. Cell Sci.* **107(Pt 8)**, 2299-2311 (1994).
4. Pekny, M., Eliasson, C., Chien, C.L., et al. GFAP-deficient astrocytes are capable of stellation *in vitro* when cocultured with neurons and exhibit a reduced amount of intermediate filaments and an increased cell saturation density. *Exp. Cell Res.* **239(2)**, 332-343 (1998).
5. Rutka, J.T. and Smith, S.L. Transfection of human astrocytoma cells with glial fibrillary acidic protein complementary DNA: Analysis of expression, proliferation, and tumorigenicity. *Cancer Res.* **53(15)**, 3624-3631 (1993).
6. Liedtke, W., Edelmann, W., Chiu, F.C., et al. Experimental autoimmune encephalomyelitis in mice lacking glial fibrillary acidic protein is characterized by a more severe clinical course and an infiltrative central nervous system lesion. *Am. J. Pathol.* **152(1)**, 251-259 (1998).
7. Li, R., Messing, A., Goldman, J.E., et al. GFAP mutations in Alexander disease. *Int. J. Dev. Neurosci.* **20(3-5)**, 259-268 (2002).
8. Hagemann, T.L., Gaeta, S.A., Smith, M.A., et al. Gene expression analysis in mice with elevated glial fibrillary acidic protein and Rosenthal fibers reveals a stress response followed by glial activation and neuronal dysfunction. *Hum. Mol. Genet.* **14(16)**, 2443-2458 (2005).
9. Ishigami, A., Masutomi, H., Handa, S., et al. Mass spectrometric identification of citrullination sites and immunohistochemical detection of citrullinated glial fibrillary acidic protein in Alzheimer's disease brains. *J. Neurosci. Res.* **93(11)**, 1664-1674 (2015).
10. Lazarus, R.C., Buonora, J.E., Flora, M.N., et al. Protein citrullination: A proposed mechanism for pathology in traumatic brain injury. *Front. Neurol.* **6:204**, (2015).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM